Multiple Sclerosis Drugs Market Companies to Watch Post-COVID

The global multiple sclerosis drugs market size is projected to reach USD 40.66 billion by 2027, exhibiting a CAGR of 7.1% during the forecast period. High prevalence of multiple sclerosis (MS) worldwide will be the primary factor driving the growth of this market, states Fortune Business Insights™ in its report, titled "Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection (Intramuscular, Subcutaneous, and Intravenous) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast, 2020-2027".

MS is a widespread degenerative neurological condition among young adults around the world. According to the Multiple Sclerosis Trust, approximately 2.5 million people worldwide are suffering from MS, with a higher number of women getting affected with the condition than men. In the UK, Public Health England, the UK government's health agency, found that between 2018 and 2020, the number of MS patients rose to 131,720. In the US, on the other hand, data from the National Multiple Sclerosis Society revealed that nearly 1 million people in the US are living with MS. Increasing incidence of this condition, therefore, is expected to surge the MS drugs market growth.

List of Key Players Covered in the Multiple Sclerosis Drugs Market Report:

Bristol-Myers Squibb Company (New York, U.S.)
Sanofi (Paris, France)
Novartis AG (Basel, Switzerland)
Pfizer Inc. (New York, U.S.)
Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
Merck & Co., Inc. (New Jersey, U.S.)
Hoffmann-La Roche Ltd. (Basel, Switzerland)
Biogen (Massachusetts, U.S.)
Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Global Multiple Sclerosis Drugs Market Highlights:

The Multiple Sclerosis Drugs Market report offers an in-depth analysis of the Multiple Sclerosis Drugs industry and the demand drivers by highlighting information on several aspects of the market. Prudent Markets addresses all these aspects and provides the latest scoop and detailed eye-opening study on all major & emerging business segments. In addition to this, the report sheds light on the industry developments by key players, which are contributing to the expansion of this industry. The development scope, feasibility study, Multiple Sclerosis Drugs market concentration, and maturity analysis is elaborated in this report.

Information given in the research report pertains to different technological advancements introduced in recent years, which allows for a meticulous analysis of the industry and offers a more comprehensive understanding to the readers.

The global economy has plunged into turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, and some are in serious trouble. The healthcare industry is experiencing mixed impact of this pandemic. Navigating through these challenging times is a mammoth task and to aid you in your journey, Fortune Business Insights™ aims at equipping your business with the most comprehensive market intelligence, collated and analyzed by our expert and experienced research team.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Mayzent's FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis. This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient's quality of life, which will contribute to the growth of the market. 

Regional Analysis:

North America (the USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
Latin America (Brazil, Mexico and Rest of Latin America)
Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Regional Insights

Healthy Awareness about MS to Feed Market Growth in North America

North America boasted a market size of USD 14.74 billion in 2019 on account of widespread awareness about MS and its treatments. In the US, government bodies such as the Multiple Sclerosis Association of America conducts educational drives during the month of March, which is recognized as the Multiple Sclerosis Awareness Month in the country.

Europe is expected to hold a prominent position in the multiple sclerosis drugs market share during the forecast period owing to supportive health reimbursement policies. In Asia Pacific, the market is anticipated to perform remarkably well as pharmaceutical companies are aggressively expanding their distribution networks across the region.

Multiple Sclerosis Drugs Highlights of the Report:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/multiple-sclerosis-drugs-market-100386

Detailed Table of Content:

1 Market Overview

1.1 Multiple Sclerosis Drugs Introduction

1.2 Market Analysis by Type

1.3 Market Analysis by Applications

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2020-2026)

1.4.1.2 Canada Market States and Outlook (2020-2026)

1.4.1.3 Mexico Market States and Outlook (2020-2026)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2020-2026)

1.4.2.2 France Market States and Outlook (2020-2026)

1.4.2.3 UK Market States and Outlook (2020-2026)

1.4.2.4 Russia Market States and Outlook (2020-2026)

1.4.2.5 Italy Market States and Outlook (2020-2026)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2020-2026)

1.4.3.2 Japan Market States and Outlook (2020-2026)

1.4.3.3 Korea Market States and Outlook (2020-2026)

1.4.3.4 India Market States and Outlook (2020-2026)

1.4.3.5 Southeast Asia Market States and Outlook (2020-2026)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2020-2026)

1.4.4.2 Egypt Market States and Outlook (2020-2026)

1.4.4.3 Saudi Arabia Market States and Outlook (2020-2026)

1.4.4.4 South Africa Market States and Outlook (2020-2026)

1.4.4.5 Turkey Market States and Outlook (2020-2026)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.